The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 14.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading neutral. Over the past year the shares are up 101%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (14 analysts) rates it strong buy, with a mean price target of $32. Insiders have been net sellers over the past quarter.
Core Scientific, Inc.
CORZ · Nasdaq · USD · Market cap $4.7B · 325 employees
Core Scientific, Inc.
FAIL · Does not pass the screenPrice as of 13 Nov 2026Daily close, not a live quoteLast reviewed 4 days ago
Screened 2026-11-13 · the tape above runs as of 02:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price14.52 USD at the 13 Nov 2026 close
- Our value readUndervalued vs our fair value, as of 13 Nov 2026
- Our regime readMarkup, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans heavily to calls (put/call 0.12)
- Last reviewed13 Nov 2026 (4 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $14.40 to $20.54, base estimate $17.86 (screen dated 2026-11-13).
- Trend Markup
- Insiders insiders sold, $135,594, latest filing 2026-10-26
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.12, read 2026-11-13
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
Core Scientific, Inc. holds its Markup at $14.52. Consolidating, no directional conviction, held for 9 days.
| Phase | Markup |
| Quantitative state | Consolidating, no directional conviction, held for 9 days |
| Price at the screen | $14.52 |
| Valuation | N/A trailing · 43.28 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 5.56 |
Five Screens, Shown in Full
Does not pass. Debt ratio
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 49.52% | Below 33% | Interest-bearing debt is 49.5% of its assets, above the one-third ceiling the screen allows. | Fail |
| Interest-bearing cash | 0.00% | Below 33% | Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. | Pass |
| Receivables | 27.62% | Below 49% | Money owed to the company is 27.6% of assets, under the 49% limit. | Pass |
| Revenue purity | 1.03% | Below 5% | Only 1.0% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
Core Scientific,'s business is in a permissible area, but its interest-bearing debt is about 50% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-15. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when CORZ's ethical verdict changes
Today CORZ does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 13 Nov 2026: it trades at roughly a 19% discount to our $17.86 fair value, 187.10% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-13 screen. The gold marker is the market price at the same screen. A 18.7% discount to the base estimate.
Third-party analyst targets: 21 covering, consensus Strong Buy. The average target sits +86% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere our models see it going: fair-value estimate $17.86, with a range of $14.40 to $20.54, dated to the 2026-11-13 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsCrypto power plays rarely deliver steady profits
Picture a warehouse packed with humming servers that mine digital coins one month and host corporate data the next. Core Scientific supplies the electricity, cooling and floor space for exactly that mix. Revenue is rising fast at 45 percent, yet the business still posts zero profit margins and carries a forward multiple above seventy times earnings.
That combination leaves little room for error. The shares already sit six percent above our fair value and the market is pricing in flawless execution in a sector known for sudden power-price spikes and coin-price crashes. Strong analyst targets exist, but they sit well ahead of any visible earnings runway.
Risk sits in the absence of a proven moat and the total dependence on volatile digital-asset demand. Even with an ethical screen pass, the valuation offers no margin of safety today. Analysis, not advice.
| Forward P/E | 43.3xcheap for a company growing this fast |
| EPS, trailing | -0.33 |
| EPS, forward | 0.34 |
| Revenue growth | +187.1%growing very fast |
| Profit margin | -18.3%currently unprofitable |
| FCF yield | -20.50% |
| Current ratio | 0.68below 1: short-term bills exceed liquid assets |
| Beta | 5.56much more volatile than the market |
| Short interest, float | 0.26% |
| 52-week range | 10.59 - 30.46 |
| Market cap | $4.7B |
| Employees | 325 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeCORZ trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 10.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Over the past year the shares are up 101%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (14 analysts) rates it strong buy, with a mean price target of $32. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 7.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Over the past year the shares are up 101%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (14 analysts) rates it strong buy, with a mean price target of $32. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Over the past year the shares are up 101%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (14 analysts) rates it strong buy, with a mean price target of $32. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Over the past year the shares are up 101%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (14 analysts) rates it strong buy, with a mean price target of $32. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 8.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Over the past year the shares are up 101%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (14 analysts) rates it strong buy, with a mean price target of $32. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Over the past year the shares are up 101%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (14 analysts) rates it strong buy, with a mean price target of $32. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 10.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Over the past year the shares are up 101%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (14 analysts) rates it strong buy, with a mean price target of $32. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 4.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Over the past year the shares are up 101%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (14 analysts) rates it strong buy, with a mean price target of $32. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 5.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 101%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (14 analysts) rates it strong buy, with a mean price target of $32. Insiders have been net sellers over the past quarter.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Core Scientific (CORZ): Can CoreWeave (CRWV) Revenue Growth Offset Expansion Risks? Yahoo Finance · 2d ago
- Meet ‘Captain Keel,’ the 37-year-old steering a Bitcoin miner into the AI data center gold rush Yahoo Finance · 3d ago
- Surging Earnings Estimates Signal Upside for Core Scientific, Inc. (CORZ) Stock Yahoo Finance · 4d ago
- Applied Digital Sinks 8% as Nebius Outlook and NVIDIA CEO Exit Hit AI Data Center Stocks; Cipher Digital Falls 4%, TeraWulf Slides 3% Yahoo Finance · 5d ago
- Wall Street Analysts See a 91.83% Upside in Core Scientific, Inc. (CORZ): Can the Stock Really Move This High? Yahoo Finance · 5d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-26 | Duchene Todd M | See remarks | S - Sale | 10,000 | $135,594 |
| 2026-10-19 | Duchene Todd M | See remarks | S - Sale | 10,000 | $138,744 |
| 2026-10-12 | Duchene Todd M | See remarks | S - Sale | 10,000 | $151,160 |
| 2026-10-05 | Duchene Todd M | See remarks | S - Sale | 10,000 | $163,056 |
| 2026-09-28 | Duchene Todd M | See remarks | S - Sale | 10,000 | $167,586 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $22.95 | +11.9% | · | $1,119 | +11.9% |
| 2 months | $18.32 | +40.2% | · | $1,402 | +40.2% |
| 3 months | $16.24 | +58.2% | · | $1,582 | +58.2% |
| 6 months | $17.40 | +47.6% | · | $1,476 | +47.6% |
| 1 year | $12.77 | +101.2% | · | $2,012 | +101.2% |
| 2 years | $8.21 | +212.9% | · | $3,129 | +212.9% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever CORZ does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.